Urinary [TIMP-2] × [IGFBP7] and serum procalcitonin to predict and assess the risk for short-term outcomes in septic and non-septic critically ill patients.
Acute kidney injury
Intensive care unit
Procalcitonin
Sepsis
[TIMP-2] × [IGFBP7]
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
21 Apr 2020
21 Apr 2020
Historique:
received:
23
09
2019
accepted:
13
04
2020
entrez:
23
4
2020
pubmed:
23
4
2020
medline:
23
4
2020
Statut:
epublish
Résumé
Biomarkers can play a critical role by facilitating diagnosis and stratification of disease, as well as assessment or prediction of disease severity. Urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor binding protein 7 product ([TIMP-2] × [IGFBP7]) predict the development and progression of AKI and recently procalcitonin (PCT), a widely used biomarker for sepsis diagnosis and management, has been associated with AKI occurrence in ICU patients. To assess combinations of [TIMP-2] × [IGFBP7] and PCT results for prediction and risk stratification of short-term outcomes in septic and non-septic patients, a retrospective cohort analysis of critically ill patients was performed in a multidisciplinary ICU. ROC curve analysis was used in order to evaluate predictive performance of combined results of [TIMP-2] × [IGFBP7] and PCT at the time of admission for AKI development. To verify the utility of adding [TIMP-2] × [IGFBP7] and PCT results for risk assessment, we evaluated the predictive value of having a single-marker positivity compared to a double-marker positivity using the widely used cut-off of 0.3 (ng/mL) 433 patients were analysed, of whom 168 had AKI within 48 h (93 septic and 65 non-septic patients). Combination of [TIMP-2] × [IGFBP7] and PCT showed a good predictive ability for AKI occurrence (AUC 0.81, 95% CI 0.77-0.86, p < 0.001, Sens 78%, Spec 73%). Combinations of biomarkers increased the odd ratios (OR) considerably. A single-marker positivity showed a fourfold risk increase, while the double-marker positivity a 26-fold risk increase for AKI occurrence. Moreover, the double-marker positivity showed an elevated risk for AKD at 7 days in non-septic patients (OR 15.9, 95% CI 3,21-73,57, p < 0.001) and for mortality within 7 days in septic patients (HR 4.1, 95% CI 1.4-11.8, p = 0.001). Although combining the results of [TIMP-2] × [IGFBP7] and PCT may be a useful tool to identify and stratify ICU patients at high risk for septic AKI and short-term adverse outcomes, data should be confirmed in a large prospective study.
Sections du résumé
BACKGROUND
BACKGROUND
Biomarkers can play a critical role by facilitating diagnosis and stratification of disease, as well as assessment or prediction of disease severity. Urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor binding protein 7 product ([TIMP-2] × [IGFBP7]) predict the development and progression of AKI and recently procalcitonin (PCT), a widely used biomarker for sepsis diagnosis and management, has been associated with AKI occurrence in ICU patients. To assess combinations of [TIMP-2] × [IGFBP7] and PCT results for prediction and risk stratification of short-term outcomes in septic and non-septic patients, a retrospective cohort analysis of critically ill patients was performed in a multidisciplinary ICU. ROC curve analysis was used in order to evaluate predictive performance of combined results of [TIMP-2] × [IGFBP7] and PCT at the time of admission for AKI development. To verify the utility of adding [TIMP-2] × [IGFBP7] and PCT results for risk assessment, we evaluated the predictive value of having a single-marker positivity compared to a double-marker positivity using the widely used cut-off of 0.3 (ng/mL)
RESULTS
RESULTS
433 patients were analysed, of whom 168 had AKI within 48 h (93 septic and 65 non-septic patients). Combination of [TIMP-2] × [IGFBP7] and PCT showed a good predictive ability for AKI occurrence (AUC 0.81, 95% CI 0.77-0.86, p < 0.001, Sens 78%, Spec 73%). Combinations of biomarkers increased the odd ratios (OR) considerably. A single-marker positivity showed a fourfold risk increase, while the double-marker positivity a 26-fold risk increase for AKI occurrence. Moreover, the double-marker positivity showed an elevated risk for AKD at 7 days in non-septic patients (OR 15.9, 95% CI 3,21-73,57, p < 0.001) and for mortality within 7 days in septic patients (HR 4.1, 95% CI 1.4-11.8, p = 0.001).
CONCLUSIONS
CONCLUSIONS
Although combining the results of [TIMP-2] × [IGFBP7] and PCT may be a useful tool to identify and stratify ICU patients at high risk for septic AKI and short-term adverse outcomes, data should be confirmed in a large prospective study.
Identifiants
pubmed: 32318859
doi: 10.1186/s13613-020-00665-9
pii: 10.1186/s13613-020-00665-9
pmc: PMC7174532
doi:
Types de publication
Journal Article
Langues
eng
Pagination
46Références
Crit Care. 2013 Feb 06;17(1):R25
pubmed: 23388612
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Crit Care Med. 2019 Oct;47(10):e820-e826
pubmed: 31343478
Crit Care Med. 2006 Jul;34(7):1996-2003
pubmed: 16715031
Contrib Nephrol. 2018;193:100-112
pubmed: 29393129
Blood Purif. 2019;47(1-3):140-148
pubmed: 30336490
Intensive Care Med. 2015 Aug;41(8):1411-23
pubmed: 26162677
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Semin Nephrol. 2015 Jan;35(1):12-22
pubmed: 25795496
J Infect Chemother. 2015 Apr;21(4):257-63
pubmed: 25677555
Kidney Int. 2013 Sep;84(3):457-67
pubmed: 23636171
Res Vet Sci. 2012 Oct;93(2):921-7
pubmed: 22001598
Nephrol Dial Transplant. 2016 Jan;31(1):16-22
pubmed: 26044835
Med Intensiva. 2018 Oct;42(7):399-408
pubmed: 29433841
Crit Care. 2016 Mar 15;20:69
pubmed: 26983854
Biostatistics. 2000 Jun;1(2):123-40
pubmed: 12933515
Crit Care. 2018 Jul 4;22(1):168
pubmed: 29973233
Am J Respir Crit Care Med. 2014 Apr 15;189(8):932-9
pubmed: 24559465
Nat Rev Nephrol. 2018 Oct;14(10):607-625
pubmed: 30135570
Kidney Int. 2015 Jan;87(1):62-73
pubmed: 25317932
Nephrology (Carlton). 2018 Dec;23(12):1090-1095
pubmed: 28967168
Angiology. 2015 Nov;66(10):957-63
pubmed: 25688117
Crit Care. 2018 Aug 3;22(1):188
pubmed: 30075798
Surg Infect (Larchmt). 2018 Feb/Mar;19(2):131-136
pubmed: 29356604
Nat Rev Nephrol. 2017 Apr;13(4):241-257
pubmed: 28239173
Sci Rep. 2019 Mar 18;9(1):4777
pubmed: 30886220
Crit Care Med. 2016 Oct;44(10):1851-60
pubmed: 27355527
JAMA. 2016 Feb 23;315(8):762-74
pubmed: 26903335
Crit Care Med. 2006 Oct;34(10):2596-602
pubmed: 16915118
Headache. 2014 Mar;54(3):472-84
pubmed: 24512072
Nephrol Dial Transplant. 2014 Nov;29(11):2054-61
pubmed: 25237065
Crit Care. 2017 Mar 25;21(1):77
pubmed: 28340605
Crit Care Med. 2000 Feb;28(2):458-61
pubmed: 10708183